Abstract：
FOXD2 adjacent opposite strand RNA 1 (FOXD2-AS1) is a long non-coding RNA being transcribed from a locus on chromosome 1p33. This transcript has been found to be up-regulated in tumor samples of almost all types of malignancies in association with a significant increase in malignant features. FOXD2-AS1 can affect activity of PI3K/AKT, AKT/mTOR, Hippo/YAP, Notch, NRf2, Wnt/β-catenin, NF-ƙB and ERK/MAPK pathways. Furthermore, it can enhance stem cell properties in cancer cells and prompt epithelial-mesenchymal transition. It is also involved in induction of resistance to a variety of anticancer agents such as adriamycin, cisplatin, 5-fluorouracil, temozolomide and gemcitabine. This article summarizes the impact of FOXD2-AS1 in diverse human disorders.
摘要：
FOXD2相邻相对链RNA1（FOXD2-AS1）是从染色体1p33上的基因座转录的长非编码RNA。已发现该转录物在几乎所有类型的恶性肿瘤的肿瘤样品中上调,与恶性特征的显著增加相关。FOXD2-AS1可以影响PI3K/AKT的活性，AKT/mTOR,河马/YAP,缺口,NRf2，Wnt/β-catenin，NF-κB和ERK/MAPK通路。此外，它可以增强癌细胞中的干细胞特性，并促进上皮-间质转化。它还参与诱导对多种抗癌剂如阿霉素，顺铂,5-氟尿嘧啶,替莫唑胺和吉西他滨。本文总结了FOXD2-AS1在各种人类疾病中的影响。
